Lung Cancer Articles

Advances Continue With Targeted Agents in ALK+ NSCLC
Paul K. Paik, MD, discusses treatment advances and sequencing strategies for patients with ALK-positive NSCLC.
Expert Discusses Frontline Osimertinib Approval and Next Steps in EGFR+ NSCLC
Helena A. Yu, MD, discusses sequencing strategies in EGFR-mutant NSCLC, the impact of osimertinib in the frontline setting, and the questions surrounding dacomitinib’s intriguing data in this landscape.
Hellman Expands on TMB Testing in Lung Cancer
Matthew D. Hellmann, MD, discusses the expansion of biomarkers across single-agent and combination therapies in patients with non–small cell lung cancer. 
FDA Approves Frontline Osimertinib for NSCLC
The FDA has approved osimertinib as a first-line treatment for patients with non–small cell lung cancer whose tumors harbor EGFR mutations (exon 19 deletions or exon 21 L858R substitution mutations).
FDA Grants Nivolumab Priority Review for SCLC
The FDA has granted a priority review to a supplemental biologics license application for nivolumab (Opdivo) for the treatment of patients with small cell lung cancer with disease progression following 2 or more lines of therapy.
Mutation Burden May Help Guide First-Line Immunotherapy in NSCLC
Tumor mutational burden in non–small cell lung cancer identified patients who were more likely to respond to first-line combination immunotherapy with nivolumab and ipilimumab, an updated analysis of CheckMate-586 clinical trial data showed.
Frontline Atezolizumab Benefit in NSCLC Sustained Across Biomarker-Driven Subgroups
Adding atezolizumab to chemotherapy and an angiogenesis inhibitor led to significant improvement in progression-free survival for patients with untreated advanced nonsquamous non-small cell lung cancer.
Expert Unveils Untapped Potential in Radiotherapy for NSCLC
Ashley A. Weiner, MD, PhD, discusses the expansions and limitations of radiotherapy in patients with non–small cell lung cancer and ongoing efforts to enhance administration and efficacy.
Frontline Nivolumab/Ipilimumab Reduces Progression Risk by 42% in TMB-High NSCLC
The combination of nivolumab and ipilimumab more than tripled the 1-year progression-free survival rate versus chemotherapy for treatment-naïve patients with non–small cell lung cancer with high tumor mutation burden.
Neoadjuvant Nivolumab Elicits Encouraging Pathologic Response Rate in Resectable NSCLC
Neoadjuvant treatment with nivolumab demonstrated a 45% major pathologic response rate in patients with resectable stage I to III non–small cell lung cancer irrespective of PD-L1 expression.
Publication Bottom Border
Border Publication